According to Medigene AG's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.71437. At the end of 2023 the company had a P/E ratio of -4.39.
Year | P/E ratio | Change |
---|---|---|
2023 | -4.39 | -63.07% |
2022 | -11.9 | -14.98% |
2021 | -14.0 | 134.25% |
2020 | -5.97 | -39.59% |
2019 | -9.88 | -44.31% |
2018 | -17.7 | -48.46% |
2017 | -34.4 | -30.61% |
2016 | -49.6 | 119.45% |
2015 | -22.6 | 42.62% |
2014 | -15.8 | 142.16% |
2013 | -6.54 | -13.4% |
2012 | -7.55 | -166.2% |
2011 | 11.4 | -240.5% |
2010 | -8.12 | -27.4% |
2009 | -11.2 | 18.38% |
2008 | -9.45 | -17.33% |
2007 | -11.4 | -74.58% |
2006 | -45.0 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.